Table 1.
Characteristics of the enrolled patients.
| Characteristic | UC (n = 147) | CD (n = 127) |
|---|---|---|
| Male | 91 (61.9) | 90 (70.9) |
| Age (initial VDZ treatment), y | 48.5 ± 14.2 | 39.8 ± 15.4 |
| Body mass index, kg/m2 | 23.0 ± 3.48 | 21.8 ± 4.03 |
| Duration of disease, y | 3.9 (1.6-8.9) | 3.1 (1.5-6.9) |
| Biologic-naïve | 3.0 (0.9-7.8) | 1.7 (0.8-4.5) |
| Biologic-exposed | 4.8 (2.3-10.0) | 4.9 (2.7-8.9) |
| Smoking status | ||
| Current smoker | 6 (4.1) | 11 (8.7) |
| Former smoker | 18 (12.2) | 11 (8.7) |
| Never | 118 (80.3) | 103 (81.1) |
| Disease extent | ||
| Proctitis | 27 (18.4) | — |
| Left-sided colitis | 44 (29.9) | — |
| Pancolitis | 75 (51.0) | — |
| Ileal | — | 42 (33.1) |
| Colonic | — | 17 (13.4) |
| Ileocolonic | — | 68 (53.5) |
| Perianal | — | 8 (6.3) |
| Disease behavior | ||
| Inflammatory | — | 58 (45.7) |
| Stricture | — | 39 (30.7) |
| Penetrating | — | 26 (20.5) |
| Mayo score | 9.2 ± 2.3 | — |
| CDAI | — | 239.5 ± 89.0) |
| Previous surgical history | 16 (10.9) | 47 (37.0) |
| Bowel resections | 9 (6.1) | 43 (33.9) |
| Surgery for perianal disease | 8 (5.4) | 20 (15.7) |
| Previous malignancy history | 3 (2.0) | 0 (0) |
| IBD-related cancer history | 2 (1.4) | 0 (0) |
| HBV infection | 21 (14.3) | 9 (7.1) |
| HBsAg positive | 15 (10.2) | 7 (5.5) |
| QuantiFERON test | ||
| Positive | 5 (3.4) | 4 (3.1) |
| Intermediate | 5 (3.4) | 1 (0.8) |
| Prior anti-TNF exposure | 43 (29.3) | 63 (49.6) |
| Adalimumab | 21 (48.8) | 61 (96.8) |
| Infliximab | 20 (46.5) | 2 (3.2) |
| Golimumab | 2 (4.6) | 0 (0) |
| Concurrent medications at the time of VDZ initiation | ||
| Immunosuppressants | 88 (59.9) | 70 (55.1) |
| Steroids | 108 (73.5) | 68 (53.5) |
Values are n (%), mean ± SD, or median (interquartile range).
Abbreviations: CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; IBD, inflammatory bowel disease; TNF, tumor necrosis factor; UC, ulcerative colitis; VDZ, vedolizumab.